ReviewCancers2022
Harnessing Antitumor CD4
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
- Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC.Journal for immunotherapy of cancer · 2025Article
- Closer proximity of pre-treatment CD4Translational lung cancer research · 2025Article
- Article
- Role of CD4Journal of translational medicine · 2025Review
- Tumor secretome shapes the immune landscape during cancer progression.Journal of experimental & clinical cancer research : CR · 2025Review
- Advances in cancer immunotherapy and future directions in personalized medicine.Open life sciences · 2025Review
- Nanoengineered-based delivery systems to modulate CD4Frontiers in pharmacology · 2025Review
- Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models.Frontiers in oncology · 2025Article
- Predictive value of peripheral blood CD4Frontiers in immunology · 2025Article
- Article
- Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.The Journal of clinical investigation · 2024Article
- Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer.iScience · 2024Article
- Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGITScientific reports · 2024Article
- Immune cell infiltration and inflammatory landscape in primary brain tumours.Journal of translational medicine · 2024Article
- Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.Medical oncology (Northwood, London, England) · 2024Article
- Epigenetic regulation of tumor-immune symbiosis in glioma.Trends in molecular medicine · 2024Review
- Development and validation of a prognostic prediction model for cervical cancer patients treated with radical radiotherapy: a study based on TCGA database.Translational cancer research · 2024Article
- Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer.BMC genomics · 2024Article
- Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decades, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.